Ocular Clinical Trials

Clinical Research Portfolio & Ophthalmic Site Capabilities

Ocular Clinical Trials partners with global pharmaceutical sponsors and medical device innovators to accelerate market access for next-generation eye care solutions. Led by Founder and Principal Investigator Dr. Bridgitte Shen Lee—a distinguished industry Key Opinion Leader—our premier clinical research site operates alongside Vision Optique, an elite private practice and multi-specialty ocular health hub established in Houston in 1999.

This integrated ecosystem provides a highly compliant framework backed by a large, diverse patient base. With a proven track record of successfully executing 24 FDA-regulated studies (Phases I–IV & IITs) involving 500+ participants, our site delivers an elite investigational infrastructure optimized for rapid enrollment, immaculate regulatory compliance, and pristine data capture.

Core Areas of Clinical Investigation

🔬 Contact Lens Studies

We participate in clinical trials to help develop next-generation contact lens technologies and solutions. Investigational tracks include:

• Testing novel lens materials for superior oxygen permeability, hydration, optimal visual performance, and long-term wearer comfort.
• Evaluating specialty lens designs for astigmatism, presbyopia, and myopia management.
• Studying the biochemical effects of advanced lens care systems on ocular surface health.
• Developing smart contact lenses engineered with integrated, built-in drug delivery architectures.

🧪 Ophthalmic Pharmaceutical Research

Our research team actively partners with leading global eye care companies to study and develop targeted therapies designed to diagnose, treat, or prevent complex diseases of the eye. Our pipeline focus includes:

• Formulating specialized pharmaceutical agents suitable for targeted topical ocular delivery, including advanced eye drops, ointments, and innovative nasal sprays.
• Evaluating the clinical endpoints, safety, and efficacy of novel ocular drugs through rigorous, FDA-regulated protocols.
• Investigating pioneering therapies for presbyopia management alongside advanced dry eye disease, Demodex blepharitis, ocular rosacea, and severe allergic conjunctivitis.

👁️ Myopia Management

Ocular Clinical Trials (OCT) possesses a robust history of executing innovative clinical protocols to manage and slow the progression of myopia (nearsightedness), particularly in children and adolescents. High myopia exponentially increases the risk for sight-threatening eye conditions later in life, such as retinal detachment, glaucoma, cataracts, and myopic maculopathy.

Leveraging our proven background in conducting both specialized ophthalmic lens and contact lens myopia management studies, our clinical trials evaluate the longitudinal efficacy and safety of advanced treatment interventions:

• Deploying specialty myopia control spectacle lenses and daytime soft contact lenses.
• Evaluating advanced nighttime Orthokeratology (Ortho-K) lens materials.
• Optimizing low-dose atropine eye drop therapeutic regimens.

🤖 Diagnostic AI Technology & Equipment

Our site accelerates the clinical integration of AI-powered diagnostic systems and next-generation ophthalmic imaging platforms. Leveraging our tech-forward investigational infrastructure, our pipeline focus includes:

• Testing and validating intelligent algorithms that enable earlier detection, highly accurate mapping, and precise monitoring of progressive ocular diseases.
• Evaluating advanced imaging hardware and machine learning applications for seamless clinical workflow deployment and baseline screening accuracy.
• Conducting data-rich device validation studies backed by our extensive, well-documented multi-specialty patient database.

High-Compliance Ophthalmic Clinical Trial Site | Houston, TX

Ocular Clinical Trials is spearheaded by Dr. Bridgitte Shen Lee, a distinguished industry Key Opinion Leader who leverages her extensive clinical expertise to lead our premier research institution. Our organization provides global pharmaceutical and medical device sponsors with an elite framework of clinical excellence, characterized by an unmatched ability to achieve rapid participant enrollment while maintaining exceptional data integrity and strict protocol execution. Our elite research team has successfully executed 24 FDA-regulated clinical studies and Investigator-Initiated Trials (IITs) involving over 500 participants since 2020.

Site Performance Metrics

Metric                                              Target / Capability

Active Patient Database            30,000+ Multi-Specialty Patients

Feasibility Response Time         Within 48 Business Hours

Investigational Framework      Phase I–IV & Investigator-Initiated Trials (IITs)

Regulatory Compliance            100% GCP / CITI Certified Staff

 Therapeutic Areas & Core Expertise

• Anterior Segment & Dry Eye: Advanced diagnostic tracking of Meibomian Gland Dysfunction (MGD), ocular surface and peri-orbital skin conditions, and targeted therapeutic endpoints.
• Contact Lens Innovation: High-volume evaluation protocols for daily disposables, multifocals, toric designs, and custom specialized lens materials.
• Myopia Management: Longitudinal pediatric studies evaluating advanced spectacle lenses, daytime contact lenses, and Ortho-K modalities.
• Digital Eye Health: Specialized evaluation frameworks tailored specifically around modern digital lifestyle and screen-related eye health issues.

Diagnostic Infrastructure & Facility Assets

• Advanced Ocular Surface Imaging: Equipped with the LipiView, LipiFlow, Firefly, and Canon slit lamp camera platforms to deliver precise, non-invasive tear film analysis and high-definition meibomian gland imaging. 
• Dedicated Research Lanes: Tightly controlled clinical examination setups reserved exclusively for clinical trial subjects to ensure absolute protocol compliance. Features two specialized 4-meter visual acuity lanes meeting strict light luminance requirements.
• Secure Investigational Product (IP) Storage: Climate-controlled, restricted-access storage rooms and high-security lockers are fully compliant with strict chain-of-custody tracking protocols.
• Real-Time Remote Monitoring Hub: High-speed fiber internet and dedicated physical workstations optimized for seamless, secure remote auditing by CRAs and monitors.
• Executive Conference Facilities: A dedicated, well-equipped conference room with high-speed fiber internet access reserved exclusively for monitors and clinical research auditors.

Principal Investigator Profile

Dr. Bridgitte Shen Lee, OD, FAAO, FBCLA, FEAOO

As a triple-fellowship optometrist and international Key Opinion Leader, Dr. Shen Lee brings over 25 years of clinical mastery and bilingual (English/Chinese) leadership to global clinical protocols. Backed by full-time, certified sub-investigators and dedicated Clinical Research Coordinators, our Houston site minimizes execution friction for global, cross-border sponsors.

Certifications: ✓ CITI Trained | ✓ Good Clinical Practice (GCP) Compliant | ✓ IATA Certified (Dangerous Goods Shipping)

Local Advantage

Based in Houston, Texas, our site has access to one of the nation’s largest and most ethnically diverse metropolitan patient populations, enabling representative recruitment. Our proximity to the Texas Medical Center—the world’s largest medical complex—also provides strong regional advantages for clinical coordination.

Corporate Collaborations & Pipeline Inquiries

We are actively seeking new study opportunities to expand our investigational pipeline. We welcome protocol collaborations, beta-site partnerships, clinical trial pipeline inquiries, and protocol valuations with industry innovators to translate advanced ophthalmic science directly into validated commercial therapies.

To discuss upcoming clinical trials or corporate advisory boards, please contact our research team directly:

• Call: (713) 838-2020, option 5
• Email: [email protected]

1) Contact Lens Wearers with Demodex Blepharitis and Dry Eye Symptoms

• Age: 18 or older
• Contact lens wearer with demodex blepharitis diagnosis and dry eye symptoms
• Real life observational study, no required study treatment, fill out in-office questionnaires
• 4 short in-person office visits over 6 months
• Total Compensation for all visits: $585, e-gift card emailed after each visit

2) Studies for Contact Lens Wearers with Dry Eye Symptoms

• Age: 18 or older
• Full time daily contact lens wearer with dry eye symptoms
• Use FDA approved Rx dry eye treatment twice/day, before and after contact lens use
• Willing to record daily time for CL application/removal, application of dry eye medication, and artificial tears application
• 3 or 4 in-person office visits over 3 months
• BENEFITS OF STUDY PARTICIPATION: complimentary dry eye treatment for 3 months, potential increase in comfortability regarding contact lens wear, and compensation for your participation
• Total Compensation after completing all visits: $325 or $400

Why Participate in a Clinical Study?

Participating in an ocular clinical trial offers valuable personal and philanthropic benefits within a highly structured, safe environment:

• Access to Innovation: Receive novel ophthalmic therapies and lens designs before they are commercially available.
• Elite Medical Oversight: Benefit from comprehensive, high-frequency eye exams and detailed assessments by expert clinical professionals.
• Advance Global Vision Care: Help shape the future of eye health, directly contributing to superior treatment options for patients worldwide.
• Study-Provided Care & Compensation: Study-related treatments, diagnostic exams, and medications are usually provided, and participants are financially compensated for their time and effort.

Connect with Our Research Group

To inquire about current active enrollments, please contact our team:

• 📞 Call: (713) 838-2020, option 5
• ✉️ Email: [email protected]

How do I know if I qualify for a clinical study?

Every clinical trial operates under a strict, FDA-approved protocol that lists specific “inclusion” and “exclusion” criteria. These rules might dictate parameters such as age limits, visual acuity scores, specific eye conditions, health history, or current medications. Our clinical research team will conduct a thorough pre-screening process, followed by an in-person diagnostic evaluation, to safely determine if a study is the right fit for you.

What is an Informed Consent Form (ICF)?

Your safety is our absolute priority. Before any study procedures begin, our team will provide you with an Informed Consent Form (ICF). This essential document clearly outlines the study’s core purpose, required timelines, visit frequencies, potential risks, and expected clinical benefits. We will review it together face-to-face, answer all of your questions, and ensure you feel completely comfortable before you choose to sign and proceed with the trial.

Scheduling & Time Commitment

What is the typical time commitment for a participant?

The schedule varies entirely by the trial’s specific protocol. Some studies require only two or three visits over a few weeks, while longitudinal tracking—such as our childhood myopia management studies—can span several months or years. We will provide you with an exact calendar of estimated visit durations before you choose to enroll.

Can I choose or change my appointment times?

Yes. We understand that our participants have busy professional, school, and family obligations. Our research coordinators work closely with you to arrange flexible visit windows that fit your life. However, because clinical protocols require data collection intervals at precise checkpoints (e.g., exactly 14 days or 3 months apart), maintaining your pre-scheduled window is critical to the data integrity and overall success of the study.

Study Compliance & Participant Responsibilities

What does “compliance” mean for a participant?

Compliance simply means following the study plan exactly as instructed by Dr. Shen Lee and the research team. This includes:

• 🗓️ Attending all visits: Arriving for all scheduled follow-up and diagnostic appointments on time.
• 👁️ Following instructions: Using the investigational eye drops, therapies, or contact lenses precisely as prescribed.
• 📝 Maintaining records: Accurately filling out any required daily participant diaries or electronic logs.
• 📢 Reporting changes: Promptly communicating any adjustments to your health, lifestyle, or concomitant medications.

What should I do if I miss a dose of my study medication or forget to wear my lenses?

If you experience a deviation from your study instructions, do not worry—but please log it immediately and notify our research coordinator as soon as possible. Transparent reporting is a cornerstone of clinical integrity, and knowing exactly what occurred helps our data managers maintain flawless, authentic records.

Can I withdraw from a study if I no longer wish to participate?

Absolutely. Your participation in any clinical study at Ocular Clinical Trials is 100% voluntary. You have the absolute legal and ethical right to withdraw from a trial at any time, for any reason, without any penalty or changes to your standard, ongoing eye care at Vision Optique.